Russia Sets First National Standard for 3D Bioprinting of Organs and Tissues
Russia has introduced its first national standard for 3D bioprinting of tissues and organs. The new framework, known as GOST, aims to bring consistency to a field that previously relied on scattered research efforts. It will take effect on September 1, 2026. The standard was developed by researchers at the National University of Science and Technology MISIS (NUST MISIS). They worked alongside industry experts and biotechnology companies to finalise the document. Consultations included input from representatives in science, medicine, and industry, ensuring the rules aligned with international best practices.
Before this, bioprinting in Russia advanced through isolated projects without a unified approach. The new GOST establishes clear principles, terminology, and safety guidelines for developing and applying bioprinting technologies. Experts argue it will improve reproducibility, enhance safety, and simplify the transition from lab experiments to clinical and industrial use. The framework also provides a regulatory path for moving innovations from research labs into real-world medical practice. Analysts suggest it will strengthen Russia's role in biomedical technologies while encouraging closer ties between research institutions and commercial partners.
The standard will officially apply from September 1, 2026. It creates a structured foundation for bioprinting, replacing earlier fragmented efforts. The goal is to accelerate progress in tissue and organ printing while ensuring safety and reliability in practical applications.
